• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Aerie misses Q4 earnings estimates by 11¢

March 1, 2018 By Sarah Faulkner

Aerie Pharmaceuticals - updatedShares in Aerie Pharmaceuticals (NSDQ:AERI) held steady today after the eye-drug maker missed earnings expectations on Wall Street with its fourth-quarter and full-year financial results.

The Durham, N.C.-based company posted a net loss of -$58.5 million, or -$1.60 per share, for the 3 months ended Dec.31.

Adjusted to exclude 1-time items, earnings per share were -$1.38, behind consensus on The Street, where analysts were looking for -$1.27.

For the full year, Aerie posted a net loss of -$145.1 million, or -$4.11 per share. Adjusted EPS were -$3.37, behind the -$3.25 consensus from The Street.

AERI shares were trading at $50.80 apiece today in mid-morning activity, down -0.7%.

The FDA approved Aerie’s glaucoma drug, Rhopressa, in December. The win came after an expert panel voted 9-1 in the drug’s favor. Studies have found that Rhopressa lowers elevated intraocular pressure in the eye, but analysts have noted that the twice-daily generic timolol ophthalmic solution 0.5% is more effective for patients with severe cases of glaucoma.

“We are all very proud of our 2017 accomplishments, especially the early FDA approval of Rhopressa. Our energy is now focused on managing a successful Rhopressa launch. With that, we are delighted to provide our net revenue guidance for full-year 2018, which reflects the tremendous efforts we have made thus far in preparing for commercialization, including excellent progress regarding market access. We expect to have our sales force of 100 territory managers in place and fully trained for our anticipated mid-second quarter 2018 launch of Rhopressa,” chairman & CEO Vicente Anido, Jr., said in prepared remarks.

“We are entering the year very well financed, allowing us to continue to build this company into what we believe will become a major ophthalmic pharmaceutical company with global reach.”

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Optical/Ophthalmic, Pharmaceuticals, Wall Street Beat Tagged With: Aerie Pharmaceuticals

IN CASE YOU MISSED IT

  • Tandem Diabetes Care wins CE mark for Mobi insulin pump with Control-IQ+ technology
  • Glooko adds chief strategy officer to chief medical officer’s title
  • Cordis launches 10,000-patient registry for drug-eluting balloon
  • Senseonics opens $50M public offering, $25M private placement with Abbott
  • Study links Abbott CGM use to lower risk of hospitalizations due to heart complications

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS